Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

BACKGROUND: Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer (NSCLC). In a phase II trial that was closed to accrual because of changes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Maitland, Michael L, Levine, Matthew R, Lacouture, Mario E, Wroblewski, Kristen E, Chung, Christine H, Gordon, Ilyssa O, Szeto, Livia, Ratko, Gail, Soltani, Keyoumars, Kozloff, Mark F, Hoffman, Philip C, Salgia, Ravi, Carbone, David P, Karrison, Theodore G, Vokes, Everett E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893521/
https://www.ncbi.nlm.nih.gov/pubmed/24386952
http://dx.doi.org/10.1186/1471-2407-14-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893521/
https://www.ncbi.nlm.nih.gov/pubmed/24386952
http://dx.doi.org/10.1186/1471-2407-14-5

Ejemplares similares